Health

Continue to drive global industrial innovation
to create a medical-grade, one-stop, all-scenario health ecosystem

• 5.0 RMB billion

  Fosun Pharma's subsidiary, Fosun Health Capital, won the bid to manage the first batch of "20+8" industry funds in Shenzhen, exclusively managing a RMB5.0 billion biopharmaceutical industry fund

• HANSIZHUANG (serplulimab injection)

  Independently developed by Fosun is the world’s first monoclonal antibody drug targeting PD-1 approved for the first-line treatment of small cell lung cancer.Approved for four indications in the Chinese mainland
  The first China-produced anti-PD-1 monoclonal antibody approved for marketing in Southeast Asia

• HANQUYOU (trastuzumab injection)

  The first China-developed monoclonal antibody biosimilar approved in China, Europe, and U.S.
  Launched in more than 40 countries and regions

• Yi Kai Da (ejilunsai injection)

  The first CAR-T cell therapy product approved for marketing in China
  Second-line indication approved in Chinese Mainland
  Benefited more than 600 lymphoma patients in China since its launch

• Artesun^® & Argesun^® (artesunate for injection)

  Treated more than 68 million severe malaria patients
  The second generation, Argesun^® became the world’s first artesunate injectable presented with a single solvent system that received WHO Prequalification (WHO PQ)

• Domestically-produced da Vinci Xi Surgical System

  Approved for launch by NMPA in June 2023
  The first domestically-produced da Vinci Xi Surgical System was officially put into use, achieving the localization and commercialization of the system

• 
  Focused ultrasound

  Collaborated with Insightec to establish a JV Fosun-Insightec and commenced the commercialization, clinical application and R&D of focused brain ultrasound platform in the Chinese market

• 
  New markets

  Sisram launched two products, Soprano Titanium and Alma Opus to new markets
  Breas completed domestic manufacturing conversion and upgrading of various ventilators

• Ion Bronchial Navigation Operation Control System (Ion System)

  Approved by NMPA

• 6,548 beds ¹

  Approved beds in the controlled medical institutions under Fosun Health
  1Bed count sourced from controlled subsidiaries, excluding Jianjia Healthcare, as of 31 December 2023